No Benefit to Salvage Transplant in R/R Multiple Myeloma

Long-term follow-up shows no progression-free or overall survival advantage among patients who received salvage transplant vs continuous lenalidomide plus dexamethasone.

Related Keywords

Salt Lake City ,Utah ,United States ,Heidelberg ,Baden Wüberg ,Germany ,University Of Utah ,German ,American ,Manni Mohyuddin ,Marc Andrea Baertsch ,University Hospital Heidelberg ,German Cancer Research Center ,American Society Of Hematology ,American Society ,Multiple Myeloma ,Myeloma ,Plasma Cell Myeloma ,Transplantation ,Transplant ,Biologic Therapy ,Iologics ,Transplantation Of Stem Cells ,Ransplantation Of Hematopoietic Stem Cells ,Hematopoietic Stem Cell Transplant ,Stem Cell Transplantation ,Stem Cell Therapy ,Tem Cell Haematopoietic Stem Transplant ,